Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Deffered Revenue: 2020-2024

Historic Non-Current Deffered Revenue for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $3.3 million.

  • Caribou Biosciences' Non-Current Deffered Revenue fell 55.51% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 55.51%. This contributed to the annual value of $3.3 million for FY2024, which is 45.64% down from last year.
  • According to the latest figures from FY2024, Caribou Biosciences' Non-Current Deffered Revenue is $3.3 million, which was down 45.64% from $6.1 million recorded in FY2023.
  • Caribou Biosciences' Non-Current Deffered Revenue's 5-year high stood at $22.0 million during FY2021, with a 5-year trough of $937,000 in FY2020.
  • Over the past 3 years, Caribou Biosciences' median Non-Current Deffered Revenue value was $6.1 million (recorded in 2023), while the average stood at $8.5 million.
  • As far as peak fluctuations go, Caribou Biosciences' Non-Current Deffered Revenue soared by 2,251.33% in 2021, and later plummeted by 61.75% in 2023.
  • Yearly analysis of 5 years shows Caribou Biosciences' Non-Current Deffered Revenue stood at $937,000 in 2020, then soared by 2,251.33% to $22.0 million in 2021, then fell by 27.59% to $16.0 million in 2022, then crashed by 61.75% to $6.1 million in 2023, then slumped by 45.64% to $3.3 million in 2024.